A Novel Way to Reduce Alzheimer’s Amyloid Plaque Burden, Phase 2 Clinical Trial Results of T3D-959 to be Presented by T3D Therapeutics at AAIC

New cognition/function and extensive plasma biomarker results of T3D-959 treatment from the Phase 2 PIONEER trial, in a modified intent-to treat population of mild to moderate Alzheimer’s patients will be presented at the upcoming Alzheimer’s Association International Conference (AAIC) in…